Litigation Details for Endo Pharmaceuticals Inc., and Grunenthal GbmH v. Teva Pharmaceuticals USA, Inc., and Barr Laboratories, Inc. (S.D.N.Y. 2012)
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Endo Pharmaceuticals Inc., and Grunenthal GbmH v. Teva Pharmaceuticals USA, Inc., and Barr Laboratories, Inc. (S.D.N.Y. 2012)
Docket | See Plans and Pricing | Date Filed | 2012-11-05 |
Court | District Court, S.D. New York | Date Terminated | |
Cause | 35:145 Civil Action to Obtain Patent | Assigned To | Thomas Poole Griesa |
Jury Demand | None | Referred To | Magistrate Judge Gabriel W. Go |
Patents | 6,096,339; 6,294,195; 6,309,663; 6,340,475; 6,488,963; 6,562,375; 6,635,280; 6,699,503; 6,723,340; 6,733,783; 7,776,314; 7,851,482; 8,075,872; 8,114,383; 8,192,722; 8,309,122; 8,329,216 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in Endo Pharmaceuticals Inc., and Grunenthal GbmH v. Teva Pharmaceuticals USA, Inc., and Barr Laboratories, Inc.
Biologic Drugs cited in Endo Pharmaceuticals Inc., and Grunenthal GbmH v. Teva Pharmaceuticals USA, Inc., and Barr Laboratories, Inc.
The biologic drugs covered by the patents cited in this case are See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , and See Plans and Pricing .
Details for Endo Pharmaceuticals Inc., and Grunenthal GbmH v. Teva Pharmaceuticals USA, Inc., and Barr Laboratories, Inc. (S.D.N.Y. 2012)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2012-11-05 | 1 | 6,009,690 A 1/2000 nomng 6,077,538 A 6/2000 Merrill 6,096,339 A SIZUC)U Aycrcla.l. 6,117,4$3 A 9/2000 Set]:leta…5,968,925 6,001,391 6,009,390 6,009,690 6,077,533 6,096,339 6,1 17,453 6.120.802 6,133,241 6,228,363 6,235,825…482 Patent would constitute infringement of the patent COUNT II: INFRINGEMENT OF THE ’383 PATENT …383 Patent would constitute infringement of the patent COUNT III: lNFRINGEMENT OF THE ’722 PATENT 58…United States Patent (10_) Patent N_o.: US 8,192,722 BZ Arkenau-Maric et al. (45) Date of Patent: *Jun. 5, | External link to document | |
2015-03-17 | 117 | States Patent Number 8,114,383. Summary judgment is denied with regard to United States patent numbers…November 2012 1:12-cv-08060-TPG-GWG Patent None District Court, S.D. New | External link to document | |
2015-03-17 | 148 | Compare Claim 9, U.S. Patent No. 8,114,383 B2 with Claim 8, U.S. Patent No. 8,114,383 B2. Plaintiffs… three of the six patents in suit, U.S. Patent Numbers 8,114,383 (“the ’383 Patent”), 8,309,060 (“the…of the patents asserted in that case was United States Patent Number 8,114,383. Id. That patent, the ’…States Patent Number 8,114,383. Summary judgment is denied with regard to United States patent numbers…States Patent Number 8,114,383. Summary judgment is denied with regard to United States patent numbers | External link to document | |
2015-03-27 | 157 | the basket method at 100 rpm. 3. U.S. Patent No. 6,294,195 (DTX004 7) discloses at least: hydrophilic…STIPULATION AND ORDER REGARDING U.S. PATENT NO. 8,309,122 AND U.S. PATENT NO. 8,329,216: Endo and Defendants…AND ORDER REGARDING U.S. PATENT NO. 8,309,122 AND U.S. PATENT NO. 8,329,216 Case 1:… each limitation of each' 122 and '216 patent claim asserted against them (as set forth in Exhibit…claims 49, 55 and 66 ofthe '216 patent). Endo need not present any proof of infringement | External link to document | |
2015-04-09 | 163 | STIPULATION AND ORDER REGARDING U.S. PATENT NO. 8,309,122 AND U.S. PATENT NO. 8,329,216: As used in the asserted…STIPULATION AND ORDER REGARDING U.S. PATENT NO. 8,309,122 AND U.S. PATENT NO. 8,329,216" dated March 27, 2015…STIPULATION AND ORDER REGARDING U.S. PATENT NO. 8,309,122 AND U.S. PATENT NO. 8,329,216 Case 1:13…STIPULATION AND ORDER REGARDING U.S. PATENT NO. 8,309,122 AND U.S. PATENT NO. 8,329,216" dated March…asserted claims of U.S. Patent 8,329,216 ("the '216 patent"), the term "a release rate profile designed | External link to document | |
2015-08-18 | 194 | of patents and patent claims asserted. See, e.g., Stipulation and Order Re U.S. Patent 7,851,482 (Doc…Agreement was executed, JMI was awarded a patent, Number 7,851,482, concerning a new, low toxicity formulation… There are three patents-in-suit. Endo owns two of the patents, United States patent numbers 8,309,122…8,309,122 (“the ’122 Patent”) and 8,329,216 (“the ’216 Patent”). These patents recite a controlled release …Grünenthal owns the third patent, United States Patent Number 8,309,060 (“the ’060 Patent”), which | External link to document | |
2014-05-07 | 54 | ,3,216, and U.S. Patent No. 7,851,482-are valid. By letter dated March 26, 2014, Dechert LLP, the…whether three patents at issue in this litigation-U.S. Patent No. 8,309,122, U.S. Patent No. 8,3,216…Pharmaceuticals Inc. ("Endo") brought patent-infringement actions against 12 pharmaceutical…products that allegedly infringe Endo's OPANA® ER patents. Two of the defendant pharmaceutical companies…review does not involve the "prosecution of patent applications," and the protective order does | External link to document | |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |